Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | C1S | P09871 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434575 | 0.78 | PARP1 (0.44) | L3MBTL1ATMKMT2AHPGDPOLB | |
| SCHEMBL22668007 | 0.77 | HTT (0.37) | TSHRF2F10F12F7 | |
| SCHEMBL28119507 | 0.76 | TSHR (0.44) | TSHRF2MAPK1HTTLMNA | |
| SCHEMBL9047896 | 0.74 | TSHR (0.43) | TSHRMAPK1HTTLMNAL3MBTL1 | |
| SCHEMBL27209008 | 0.74 | ATM (0.47) | TSHRMAPK1HTTLMNAL3MBTL1 | |
| SCHEMBL3966940 | 0.74 | ATM (0.47) | TSHRMAPK1HTTLMNAL3MBTL1 | |
| SCHEMBL10513166 | 0.73 | ATM (0.50) | F2F10F12F7F3 | |
| SCHEMBL7068869 | 0.73 | TSHR (0.41) | TSHRMAPK1HTTLMNAL3MBTL1 | |
| SCHEMBL58239 | 0.73 | MAOA (0.47) | TSHRMAPK1HTTAKT1HPGD | |
| SCHEMBL29875319 | 0.73 | ALDH1A1 (0.41) | TSHRMAPK1HTTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | disclosed |
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| EP-2303021-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2959900-B1 | COMPOUND FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2016088747-A1 | HYDRAZONE DERIVATIVE AND PEST CONTROL AGENT | 日産化学工業株式会社 | 2016-06-09 | — | — | WO | disclosed |
| EP-2959900-A1 | COMPOUND FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | TSHR 2209/4885F2 522/4885F10 774/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | TSHR 4138/4885F2 1274/4885F10 1059/4885 |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | TSHR 3025/4885F2 5/4885F10 13/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | TSHR 4138/4885F2 1274/4885F10 1059/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TSHR 4138/4885F2 1274/4885F10 1059/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TSHR 4138/4885F2 1274/4885F10 1059/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | TSHR 3025/4885F2 5/4885F10 13/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TSHR 4138/4885F2 1274/4885F10 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.